Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 46 to 60 of 148 results for allergy

  1. WP1048 for treating grass pollen allergy in people aged 18 to 60 [TSID10467]

    Awaiting development Reference number: GID-TA11305 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Medicines optimisation: the safe and effective use of medicines to enable the best possible outcomes (NG5)

    This guideline covers safe and effective use of medicines in health and social care for people taking 1 or more medicines. It aims to ensure that medicines provide the greatest possible benefit to people by encouraging medicines reconciliation, medication review, and the use of patient decision aids.

    NICE guideline
    Published
    4 March 2015
    View recommendations

    Sections for NG5

  3. Modes of provision of support to healthcare professionals:- What would be the impact of dietetic telephone support to healthcare professionals to aid in the diagnosis and assessment of babies showing non-IgE-mediated food allergy symptoms in primary care and community settings?

    in the diagnosis and assessment of babies showing non-IgE-mediated food allergy symptoms in primary care and community settings? Any...

    Research recommendation
    Published
    9 June 2015

  4. Values of skin prick testing and specific IgE antibody testing and their predictive value:- Can skin prick testing and specific IgE antibody testing cut-off points be established to diagnose IgE-mediated food allergy in children and young people, and to predict the severity of reaction?

    antibody testing cut-off points be established to diagnose IgE-mediated food allergy in children and young people, and to predict the...

    Research recommendation
    Published
    9 June 2015

  5. Brensocatib for treating non-cystic fibrosis bronchiectasis in people 12 years and over ID6448

    In development Reference number: GID-TA11564 Expected publication date:  22 July 2026

    Technology appraisal guidance
    In development

  6. Nerandomilast for treating idiopathic pulmonary fibrosis or progressive pulmonary fibrosis ID6446

    In development Reference number: GID-TA11552 Expected publication date:  25 September 2026

    Technology appraisal guidance
    In development

  7. Diverticular disease: diagnosis and management (NG147)

    This guideline covers the diagnosis and management of diverticular disease in people aged 18 years and over. It aims to improve diagnosis and care and help people get timely information and advice, including advice about symptoms and when to seek help.

    NICE guideline
    Published
    27 November 2019
    View recommendations

    Sections for NG147

  8. Guidance and quality standards in consultation

    See a complete list of all our guidance and quality standards currently open for consultation

  9. Using selective cyclooxygenase 2 inhibitors in people with previous severe allergic reactions to non-selective non-steroidal anti-inflammatory drugs:- Should all patients who have experienced a severe allergic reaction to a non-selective non-steroidal anti-inflammatory drug (NSAID) be assessed by specialist drug allergy services or should they be advised to take a selective cyclooxygenase 2 (COX 2) inhibitor without further investigations if clinically appropriate?

    non-steroidal anti-inflammatory drug (NSAID) be assessed by specialist drug allergy services or should they be advised to take a...

    Research recommendation
    Published
    9 June 2015

  10. Beremagene geperpavec for treating skin wounds associated with dystrophic epidermolysis bullosa [ID3959]

    In development Reference number: GID-TA10868 Expected publication date:  15 July 2026

    Technology appraisal guidance
    In development

  11. For people who have experienced suspected anaphylaxis, what is the effect on health-related quality of life of (a) referral to specialist allergy services and (b) provision of adrenaline injectors, when compared with emergency treatment alone?

    effect on health-related quality of life of (a) referral to specialist allergy services and (b) provision of adrenaline injectors, when...

    Research recommendation
    Published
    26 October 2020

  12. Epicutaneous immunotherapy for treating peanut allergy in children [ID1255]

    Discontinued Reference number: GID-TA10763

    Technology appraisal guidance
    Discontinued

  13. Fluid-filled thermal balloon and microwave endometrial ablation techniques for heavy menstrual bleeding (TA78)

    Evidence-based recommendations on fluid-filled thermal balloon and microwave endometrial ablation techniques for heavy menstrual bleeding in adults.

    Technology appraisal guidance
    Published
    28 April 2004
    View recommendations

    Sections for TA78

  14. Healthcare-associated infections: prevention and control in primary and community care (CG139)

    This guideline covers preventing and controlling healthcare-associated infections in children, young people and adults in primary and community care settings. It provides a blueprint for the infection prevention and control precautions that should be applied by everyone involved in delivering NHS care and treatment.

    Clinical guideline
    Last updated
    15 February 2017
    View recommendations

    Sections for CG139

  15. Effect of specialist services on health-related quality of life:- For people who have experienced suspected anaphylaxis, what is the effect on health-related quality of life of (a) referral to specialist allergy services and (b) provision of adrenaline injectors, when compared with emergency treatment alone?

    effect on health-related quality of life of (a) referral to specialist allergy services and (b) provision of adrenaline injectors, when...

    Research recommendation
    Published
    9 June 2015